FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225486989> ?p ?o ?g. }

• W4225486989 endingPage "e0266922" @default.
• W4225486989 startingPage "e0266922" @default.
• W4225486989 abstract "Maintenance drugs are used to treat chronic conditions. Several classes of maintenance drugs have attracted attention because of their potential to affect susceptibility to and severity of COVID-19.Using claims data on 20% random sample of Part D Medicare enrollees from April to December 2020, we identified patients diagnosed with COVID-19. Using a nested case-control design, non-COVID-19 controls were identified by 1:5 matching on age, race, sex, dual-eligibility status, and geographical region. We identified usage of angiotensin-converting enzyme inhibitors (ACEI), angiotensin-receptor blockers (ARB), statins, warfarin, direct factor Xa inhibitors, P2Y12 inhibitors, famotidine and hydroxychloroquine based on Medicare prescription claims data. Using extended Cox regression models with time-varying propensity score adjustment we examined the independent effect of each study drug on contracting COVID-19. For severity of COVID-19, we performed extended Cox regressions on all COVID-19 patients, using COVID-19-related hospitalization and all-cause mortality as outcomes. Covariates included gender, age, race, geographic region, low-income indicator, and co-morbidities. To compensate for indication bias related to the use of hydroxychloroquine for the prophylaxis or treatment of COVID-19, we censored patients who only started on hydroxychloroquine in 2020.Up to December 2020, our sample contained 374,229 Medicare patients over 65 who were diagnosed with COVID-19. Among the COVID-19 patients, 278,912 (74.6%) were on at least one study drug. The three most common study drugs among COVID-19 patients were statins 187,374 (50.1%), ACEI 97,843 (26.2%) and ARB 83,290 (22.3%). For all three outcomes (diagnosis, hospitalization and death), current users of ACEI, ARB, statins, warfarin, direct factor Xa inhibitors and P2Y12 inhibitors were associated with reduced risks, compared to never users. Famotidine did not show consistent significant effects. Hydroxychloroquine did not show significant effects after censoring of recent starters.Maintenance use of ACEI, ARB, warfarin, statins, direct factor Xa inhibitors and P2Y12 inhibitors was associated with reduction in risk of acquiring COVID-19 and dying from it." @default.
• W4225486989 created "2022-05-05" @default.
• W4225486989 creator A5026070435 @default.
• W4225486989 creator A5031395263 @default.
• W4225486989 creator A5031594710 @default.
• W4225486989 creator A5043972897 @default.
• W4225486989 creator A5046553003 @default.
• W4225486989 creator A5073704537 @default.
• W4225486989 date "2022-04-18" @default.
• W4225486989 modified "2023-09-29" @default.
• W4225486989 title "Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients" @default.
• W4225486989 cites W1966238900 @default.
• W4225486989 cites W1969618533 @default.
• W4225486989 cites W1976659050 @default.
• W4225486989 cites W2007853672 @default.
• W4225486989 cites W2013063349 @default.
• W4225486989 cites W2028521865 @default.
• W4225486989 cites W2074162144 @default.
• W4225486989 cites W2095807050 @default.
• W4225486989 cites W2150119943 @default.
• W4225486989 cites W2150291618 @default.
• W4225486989 cites W2151432963 @default.
• W4225486989 cites W2978857406 @default.
• W4225486989 cites W3008142620 @default.
• W4225486989 cites W3008461878 @default.
• W4225486989 cites W3009912996 @default.
• W4225486989 cites W3013302817 @default.
• W4225486989 cites W3013967887 @default.
• W4225486989 cites W3014573995 @default.
• W4225486989 cites W3015946392 @default.
• W4225486989 cites W3016968765 @default.
• W4225486989 cites W3017326650 @default.
• W4225486989 cites W3017545174 @default.
• W4225486989 cites W3021591080 @default.
• W4225486989 cites W3023640683 @default.
• W4225486989 cites W3023751598 @default.
• W4225486989 cites W3024420022 @default.
• W4225486989 cites W3027984107 @default.
• W4225486989 cites W3029650736 @default.
• W4225486989 cites W3029761916 @default.
• W4225486989 cites W3030868216 @default.
• W4225486989 cites W3033168179 @default.
• W4225486989 cites W3034127876 @default.
• W4225486989 cites W3035819488 @default.
• W4225486989 cites W3035860713 @default.
• W4225486989 cites W3036031172 @default.
• W4225486989 cites W3037887855 @default.
• W4225486989 cites W3040366309 @default.
• W4225486989 cites W3047144258 @default.
• W4225486989 cites W3048086118 @default.
• W4225486989 cites W3082244519 @default.
• W4225486989 cites W3126500637 @default.
• W4225486989 cites W3132895255 @default.
• W4225486989 cites W3153043776 @default.
• W4225486989 cites W3154294714 @default.
• W4225486989 cites W3167462645 @default.
• W4225486989 cites W3181297434 @default.
• W4225486989 cites W4206619848 @default.
• W4225486989 cites W4206620568 @default.
• W4225486989 doi "https://doi.org/10.1371/journal.pone.0266922" @default.
• W4225486989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35436293" @default.
• W4225486989 hasPublicationYear "2022" @default.
• W4225486989 type Work @default.
• W4225486989 citedByCount "7" @default.
• W4225486989 countsByYear W42254869892022 @default.
• W4225486989 countsByYear W42254869892023 @default.
• W4225486989 crossrefType "journal-article" @default.
• W4225486989 hasAuthorship W4225486989A5026070435 @default.
• W4225486989 hasAuthorship W4225486989A5031395263 @default.
• W4225486989 hasAuthorship W4225486989A5031594710 @default.
• W4225486989 hasAuthorship W4225486989A5043972897 @default.
• W4225486989 hasAuthorship W4225486989A5046553003 @default.
• W4225486989 hasAuthorship W4225486989A5073704537 @default.
• W4225486989 hasBestOaLocation W42254869891 @default.
• W4225486989 hasConcept C126322002 @default.
• W4225486989 hasConcept C17923572 @default.
• W4225486989 hasConcept C2426938 @default.
• W4225486989 hasConcept C2779123688 @default.
• W4225486989 hasConcept C2779134260 @default.
• W4225486989 hasConcept C3008058167 @default.
• W4225486989 hasConcept C50382708 @default.
• W4225486989 hasConcept C524204448 @default.
• W4225486989 hasConcept C71924100 @default.
• W4225486989 hasConcept C98274493 @default.
• W4225486989 hasConceptScore W4225486989C126322002 @default.
• W4225486989 hasConceptScore W4225486989C17923572 @default.
• W4225486989 hasConceptScore W4225486989C2426938 @default.
• W4225486989 hasConceptScore W4225486989C2779123688 @default.
• W4225486989 hasConceptScore W4225486989C2779134260 @default.
• W4225486989 hasConceptScore W4225486989C3008058167 @default.
• W4225486989 hasConceptScore W4225486989C50382708 @default.
• W4225486989 hasConceptScore W4225486989C524204448 @default.
• W4225486989 hasConceptScore W4225486989C71924100 @default.
• W4225486989 hasConceptScore W4225486989C98274493 @default.
• W4225486989 hasFunder F4320337372 @default.
• W4225486989 hasIssue "4" @default.
• W4225486989 hasLocation W42254869891 @default.
• W4225486989 hasLocation W42254869892 @default.

• next